Pluri Inc. Total Liabilities
Pluri Inc. total liabilities. Based on the latest financial reports, Pluri Inc. (PLUR) has total liabilities worth $39.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pluri Inc. (PLUR) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pluri Inc. (2002–2025)
Total liabilities of Pluri Inc. from 2002 to 2025. This chart illustrates how Pluri Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Pluri Inc. Competitors by Total Liabilities
The table below lists competitors of Pluri Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
USA | $116.47 Million |
|
Trinity Watthana Public Company Limited
BK:TNITY
|
Thailand | ฿2.87 Billion |
|
Loyal Lithium Ltd.
AU:LLI
|
Australia | AU$522.00K |
|
PCCS Group Bhd
KLSE:6068
|
Malaysia | RM162.58 Million |
|
Rubberex Corporation M Bhd
KLSE:7803
|
Malaysia | RM31.72 Million |
|
Agat Ejendomme A/S
CO:AGAT
|
Denmark | Dkr502.00 Million |
|
Compugates Holdings Bhd
KLSE:5037
|
Malaysia | RM36.71 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Pluri Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Pluri Inc..
Liquidity & Leverage Metrics
Pluri Inc. Total Liabilities Ratios Explained
Pluri Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pluri Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pluri Inc. (2002–2025)
The table below shows the annual total liabilities of Pluri Inc. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $39.55 Million | +15.94% |
| 2024-06-30 | $34.11 Million | -3.90% |
| 2023-06-30 | $35.50 Million | -1.06% |
| 2022-06-30 | $35.88 Million | -1.40% |
| 2021-06-30 | $36.39 Million | +285.82% |
| 2020-06-30 | $9.43 Million | -0.61% |
| 2019-06-30 | $9.49 Million | -9.22% |
| 2018-06-30 | $10.45 Million | +43.53% |
| 2017-06-30 | $7.28 Million | -6.45% |
| 2016-06-30 | $7.79 Million | -22.24% |
| 2015-06-30 | $10.01 Million | -15.87% |
| 2014-06-30 | $11.90 Million | +9.68% |
| 2013-06-30 | $10.85 Million | +12.11% |
| 2012-06-30 | $9.68 Million | +273.09% |
| 2011-06-30 | $2.59 Million | +58.07% |
| 2010-06-30 | $1.64 Million | +53.51% |
| 2009-06-30 | $1.07 Million | -14.82% |
| 2008-06-30 | $1.25 Million | +51.25% |
| 2007-06-30 | $829.74K | -79.61% |
| 2006-06-30 | $4.07 Million | +398.09% |
| 2005-06-30 | $816.91K | -19.93% |
| 2004-06-30 | $1.02 Million | +102.35% |
| 2003-06-30 | $504.18K | +448.38% |
| 2002-06-30 | $91.94K | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more